Selected stock price target news of the day - February 13th, 2025

By: Matthew Otto

HubSpot Exceeds Q4 Earnings Expectations but Provides Mixed 2025 Guidance

HubSpot reported its financial results for the fourth quarter and full year ended December 31, 2024, posting earnings per share (EPS) of $2.32, which was $0.13 higher than the analyst estimate of $2.19. Total revenue for the quarter reached $703.2 million, exceeding the consensus estimate of $673.65 million and reflecting a 21% increase on an as-reported basis and 20% in constant currency compared to Q4 2023. Subscription revenue rose by 21% to $687.3 million, while professional services and other revenue grew by 36% to $15.9 million.

For the full year, HubSpot’s total revenue was $2.63 billion, marking a 21% growth in both as-reported and constant currency terms. Subscription revenue contributed $2.57 billion, up 21%, and professional services and other revenue increased by 24% to $58.0 million.

Operating margins showed improvement, with a GAAP operating margin of (1.5%) in Q4 2024, compared to (4.0%) in Q4 2023, while the non-GAAP operating margin increased to 18.9% from 17.1% in the previous year. HubSpot anticipates Q1 2025 EPS between $1.74 and $1.76, below the consensus of $2.01, and expects revenue between $697 million and $699 million, compared to the consensus of $705.6 million.

For the full year 2025, HubSpot forecasts EPS of $9.11 to $9.19, closely aligning with the consensus of $9.13, and projects total revenue between $2.985 billion and $2.995 billion, slightly below the consensus of $2.997 billion.

Analysts Raise Price Targets Despite Mixed 2025 Outlook

Barclays analyst Ryan Macwilliams maintained an Equal-Weight rating but raised the price target from $725 to $815.
Morgan Stanley analyst Keith Weiss continued as Overweight and lifted the price target from $835 to $898.
Canaccord Genuity analyst David Hynes kept a Buy rating and increased the price target from $710 to $900.
Piper Sandler analyst Brent Bracelin maintained a Neutral stance while raising the price target from $640 to $808.
Oppenheimer analyst Ken Wong reaffirmed an Outperform rating and boosted the price target from $850 to $900.

Which Analyst has the best track record to show on HUBS?

Analyst Ryan Macwilliams (BARCLAYS) currently has the highest performing score on HUBS with 11/12 (91.67%) price target fulfillment ratio. His price targets carry an average of $-33.43 (-4.41%) potential downside. Avantor stock price reaches these price targets on average within 74 days.

Trade Desk Reports Q4 2024 Results with EPS Beat but Revenue Miss; Issues Cautious Q1 2025 Outlook

The Trade Desk reported its financial results for the fourth quarter and full year ended December 31, 2024, showing a revenue increase of 22% year over year for the quarter, reaching $741 million, and a 26% increase for the full year, totaling $2.445 billion. Although Q4 revenue fell short of the consensus estimate of $759.05 million, Trade Desk exceeded earnings expectations with non-GAAP diluted earnings per share (EPS) of $0.59, surpassing the analyst estimate of $0.57 by $0.02. Net income for Q4 was $182 million, with a net income margin of 25%, up from $97 million and a margin of 16% in the same period in 2023.

For the full year, net income reached $393 million, reflecting a 16% net income margin compared to $179 million and 9% in 2023. Trade Desk also posted GAAP diluted EPS of $0.36 for Q4 and $0.78 for the year, showing growth from $0.19 and $0.36, respectively, in the prior year.

Non-GAAP financial metrics also showed performance, with adjusted EBITDA of $350 million for the fourth quarter, maintaining a margin of 47%, and $1.011 billion for the year with a margin of 41%. Non-GAAP net income was $297 million for Q4, up from $207 million a year earlier, while full-year non-GAAP net income was $832 million, up from $628 million in 2023. However, The Trade Desk’s Q4 revenue of $741 million missed analysts’ estimates of $759.05 million.

Additionally, Trade Desk’s guidance for first-quarter 2025 revenue of at least $575 million came in below the consensus estimate of $581.5 million. Trade Desk expects Q1 2025 adjusted EBITDA of approximately $145 million.

Analysts Lower Price Targets Amid Revenue Miss

DA Davidson analyst Tom White maintained a Buy rating yet lowered the price target from $134 to $103.
Susquehanna analyst Shyam Patil maintained a Positive rating but reduced the price target from $150 to $135.
Baird analyst Vikram Kesavabhotla reiterated an Outperform rating and lowered the price target from $160 to $145.
Morgan Stanley analyst Matthew Cost kept an Overweight rating while decreasing the price target from $145 to $132.
Needham analyst Laura Martin reiterated a Buy rating and the price target at $145.
Evercore ISI Group analyst Shweta Khajuria downgraded from Outperform to In-Line and the price target from $135 to $90.

Which Analyst has the best track record to show on TTD?

Analyst Laura Martin (NEEDHAM) currently has the highest performing score on TTD with 12/13 (92.31%) price target fulfillment ratio. Her price targets carry an average of $16.28 (14.97%) potential upside. Trade Desk stock price reaches these price targets on average within 175 days.

Biogen Exceeds Q4 Expectations but 2025 Outlook Falls Short of Analyst Projections

Biogen reported fourth-quarter revenue of $2.46 billion, surpassing Wall Street’s expectations of $2.40 billion and marking a 3% increase compared to the same period last year. Adjusted earnings per share were $3.44, exceeding analyst predictions of $3.35.

Biogen posted a net income of $266.8 million, up from $249.7 million, or $1.71 per share, in the year-earlier period. Growth was driven by cost-cutting measures and new products, including Leqembi, which generated $87 million in revenue, outperforming analyst estimates of $67 million. Skyclarys contributed $102 million, nearly doubling its sales from the previous year, while Zurzuvae posted $22.9 million in sales, slightly below the expected $26 million. However, sales from multiple sclerosis treatments fell 8% to $1.07 billion, continuing a downward trend due to generic competition.

Biogen’s 2025 earnings outlook of $15.25 to $16.25 per share fell short of Wall Street’s forecast of $16.34 per share, influenced by a 35-cent-per-share foreign exchange headwind. Additionally, Biogen projects $1 billion in gross savings, or $800 million in net savings, by the end of 2025 through its cost-cutting program. In another strategic move, Royalty Pharma agreed to provide $250 million in R&D funding for litifilimab, a potential lupus treatment in Biogen’s pipeline.

Analyst Price Target Reductions Despite Continued Buy Ratings

HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating but lowered the price target from $300 to $241.
Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and reduced the price target from $220 to $210.
Canaccord Genuity analyst Sumant Kulkarni kept a Buy rating while decreasing the price target from $298 to $265.
Needham analyst Ami Fadia reiterated a Hold rating.

Which Analyst has the best track record to show on BIIB?

Analyst Brian Skorney (BAIRD) currently has the highest performing score on BIIB with 21/29 (72.41%) price target fulfillment ratio. His price targets carry an average of $139.24 (86.61%) potential upside. Biogen stock price reaches these price targets on average within 236 days.